$248 Million is the total value of Decheng Capital Management III (Cayman), LLC's 24 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALPPRNCL | Alpine Immune Sciences, Inc. | $51,787,983 | +5.0% | 6,708,288 | 0.0% | 20.89% | +13.2% | |
| ZNTL | Zentalis Pharmaceuticals Inc. | $31,382,828 | -14.6% | 1,824,583 | 0.0% | 12.66% | -7.9% | |
| TXG | 10x Genomics, Inc. | $20,059,518 | +53.1% | 359,554 | 0.0% | 8.09% | +65.1% | |
| ILMN | Illumnia, Inc. | $18,803,760 | +15.0% | 80,859 | 0.0% | 7.59% | +24.0% | |
| PACB | Pacific Biosciences of California, Inc. | $16,951,638 | +41.6% | 1,463,872 | 0.0% | 6.84% | +52.6% | |
| Cue Health Inc. | $16,345,254 | -12.1% | 8,980,909 | 0.0% | 6.59% | -5.2% | ||
| RXDX | Sell | Prometheus Biosciences, Inc. | $16,098,000 | -41.5% | 150,000 | -40.0% | 6.50% | -36.9% |
| RCUS | Arcus BioSciences, Inc. | $15,864,970 | -11.8% | 869,790 | 0.0% | 6.40% | -4.9% | |
| ARGX | Buy | Argenx SE | $10,219,497 | +387.9% | 27,429 | +396.1% | 4.12% | +425.9% |
| HZNP | Horizon Therapeutics PLC | $8,611,146 | -4.1% | 78,900 | 0.0% | 3.47% | +3.4% | |
| TERN | Terns Pharmaceuticals, Inc. | $8,457,134 | +16.3% | 714,285 | 0.0% | 3.41% | +25.4% | |
| BYSI | New | BeyondSpring Inc. | $5,553,120 | – | 4,958,143 | +100.0% | 2.24% | – |
| SGEN | Seagen Inc. | $4,659,645 | +57.6% | 23,014 | 0.0% | 1.88% | +69.8% | |
| Aadi Bioscience, Inc. | $3,810,622 | -43.6% | 526,329 | 0.0% | 1.54% | -39.2% | ||
| MRSN | Mersana Therapeutics, Inc. | $3,716,541 | -29.9% | 904,268 | 0.0% | 1.50% | -24.4% | |
| ACET | Adicet Bio, Inc. | $3,340,800 | -35.6% | 580,000 | 0.0% | 1.35% | -30.6% | |
| EQ | Equillium Inc. | $3,246,535 | -33.6% | 4,447,308 | 0.0% | 1.31% | -28.5% | |
| Aura Biosciences, Inc. | $2,722,130 | -11.6% | 293,333 | 0.0% | 1.10% | -4.8% | ||
| ATRC | New | AtriCure Inc. | $1,917,436 | – | 46,259 | +100.0% | 0.77% | – |
| SCYX | Scynexis Inc. | $1,666,665 | +92.3% | 555,555 | 0.0% | 0.67% | +107.4% | |
| GeneDx Holdings Corp. | $1,247,909 | +38.3% | 3,418,929 | 0.0% | 0.50% | +48.8% | ||
| Apexigen, Inc. | $922,646 | -28.6% | 1,894,551 | 0.0% | 0.37% | -23.1% | ||
| Owlet, Inc. | $291,441 | -42.0% | 898,400 | 0.0% | 0.12% | -37.2% | ||
| NBSE | NeuBase Therapeutics, Inc. | $185,000 | -2.7% | 1,000,000 | 0.0% | 0.08% | +5.6% | |
| NAUT | Exit | Nautilus Biotechnology, Inc. | $0 | – | -300,000 | -100.0% | -0.20% | – |
| Exit | AtriCure Inc. | $0 | – | -46,259 | -100.0% | -0.77% | – | |
| Exit | BeyondSpring Inc. | $0 | – | -4,958,143 | -100.0% | -3.49% | – | |
| ALBO | Exit | Albireo Pharma, Inc. | $0 | – | -623,342 | -100.0% | -5.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Illumnia, Inc. | 7 | Q3 2023 | 16.5% |
| Cue Health Inc. | 7 | Q3 2023 | 17.8% |
| Arcus BioSciences, Inc. | 7 | Q3 2023 | 8.4% |
| 10x Genomics, Inc. | 7 | Q3 2023 | 8.1% |
| Pacific Biosciences of California, Inc. | 7 | Q3 2023 | 6.8% |
| Equillium Inc. | 7 | Q3 2023 | 4.3% |
| Aadi Bioscience, Inc. | 7 | Q3 2023 | 2.7% |
| Adicet Bio, Inc. | 7 | Q3 2023 | 3.6% |
| Aura Biosciences, Inc. | 7 | Q3 2023 | 6.1% |
| Terns Pharmaceuticals, Inc. | 7 | Q3 2023 | 3.4% |
View Decheng Capital Management III (Cayman), LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-01-22 |
| 13F-HR/A | 2023-12-12 |
| 13F-HR/A | 2023-11-29 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-08 |
| 4 | 2022-09-27 |
| 13F-HR | 2022-08-01 |
View Decheng Capital Management III (Cayman), LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.